Progress on grants signed before 2010

REMoxTB is a study for the “Rapid evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis”. REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy. The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin containing regimens to determine whether substitution for ethambutol makes it possible to reduce the duration of chemotherapy and whether the substitution for isoniazid improves the bactericidal activity of the regimen and permits future trials of shorter regimens without isoniazid.

The REMoxTB study has initiated the first regulatory trial of a treatment shortening regimen in tuberculosis. So far more than 1100 patients have been recruited. This project has done much to increase the delivery of regulatory standard clinical trial sites in Africa. It has also assisted in developing a wide range of tools that are necessary for future design and implementation of tuberculosis clinical trials. Discussions with other partners including the Centre for Disease Control (CDC) and the National Institute of Allergy and Infectious Diseases (NIAID) are taking place to see how this consortium can synergistically partner with other networks in innovative combinatory clinical trial designs.